Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) EPS (Basic) (2016 - 2025)

Ultragenyx Pharmaceutical has reported EPS (Basic) over the past 10 years, most recently at -$1.28 for Q4 2025.

  • Quarterly EPS (Basic) rose 7.25% to -$1.28 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.83 through Dec 2025, up 7.9% year-over-year, with the annual reading at -$5.83 for FY2025, 7.31% up from the prior year.
  • EPS (Basic) was -$1.28 for Q4 2025 at Ultragenyx Pharmaceutical, up from -$1.81 in the prior quarter.
  • Over five years, EPS (Basic) peaked at -$1.08 in Q3 2021 and troughed at -$3.5 in Q3 2022.
  • The 5-year median for EPS (Basic) is -$1.81 (2021), against an average of -$1.86.
  • Year-over-year, EPS (Basic) crashed 530.95% in 2021 and then surged 37.22% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at -$1.79 in 2021, then decreased by 20.67% to -$2.16 in 2022, then skyrocketed by 33.33% to -$1.44 in 2023, then grew by 4.17% to -$1.38 in 2024, then grew by 7.25% to -$1.28 in 2025.
  • Per Business Quant, the three most recent readings for RARE's EPS (Basic) are -$1.28 (Q4 2025), -$1.81 (Q3 2025), and -$1.17 (Q2 2025).